GlobalFoundries Inc. Ordinary Shares vs Medpace Holdings Inc — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.25 (market cap $27.51B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: GlobalFoundries Inc. Ordinary Shares is the larger of the two by market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.97% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Medpace Holdings Inc for 14 Days on average.
| GFS | MEDP | |
|---|---|---|
Market Cap | $27.51B | $16.82B |
Volume | 10,416,572 | 223,093 |
Sector | Technology | Health |
52-Week High | $89.96 | $630.19 |
52-Week Low | $32.24 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $26.80B | $16.44B |
Dividend Yield | 0.97% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →